SOURCE: BioElectronics Corporation

BioElectronics Corporation

February 18, 2009 08:30 ET

BioElectronics Begins Shipments of Next-Generation Breast Surgery Recovery Kits

Product Updated to More Effective "Loop" Design

FREDERICK, MD--(Marketwire - February 18, 2009) - BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced significant enhancements to its RecoveryRx™ breast surgery recovery kit. The product has been converted to a more efficient 12 cm loop design, which is even more effective than previous versions in reducing inflammation, bruising and pain following breast augmentation, lift or reduction. The product begins shipping immediately.

"Plastic surgeons are increasingly using our RecoveryRx product to speed healing and reduce pain following breast related cosmetic procedures. The new version of our product offers increased effectiveness in an enhanced form factor. We have received very positive reactions from our plastic surgeon customers who have come to rely on our products to help their patients recover faster with less pain," commented Andrew Whelan, CEO of BioElectronics, Corp. "We believe the increased popularity of this device can be easily explained by the success of recent clinical trials which showed that 73% of women treated with this therapy reported less pain and discomfort compared to treatment with a placebo device. We cannot imagine any women going through breast surgery without the benefit of RecoveryRx treatment -- Why experience pain when there is an inexpensive and highly effective alternative?"

About BioElectronics Corporation

BioElectronics Corporation is the maker of the Allay™ Menstrual Pain Therapy, the RecoveryRx™ Therapy, ActiPatch® Therapy, and the HealFast™ Therapy for veterinary applications, ( ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international agencies.

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Contact Information

  • Media Contact:
    Joe Noel
    Emerging Growth Research LLP
    Voice: 925-922-2560